Michael R. McLaren
Akebia Therapeutics (United States)
ORCID: 0000-0003-1575-473XAlso affiliated with Massachusetts Institute of Technology
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested β papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 4 papers. Top paper: βClostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiotaβ.
Colleen M. Pike, Ruth Parsons, Alissa J. Rivera, Matthew H. Foley, Michael R. McLaren +3 more
Colleen M. Pike, Ruth Parsons, Alissa J. Rivera, Matthew H. Foley, Michael R. McLaren +3 more
Michael R. McLaren, Alissa J. Rivera, A.D. Reed, Naga S. Betrapally, T. Burdette +5 more
Jacob T. Nearing, Amy D. Willis, Karen G. Lloyd, Benjamin J. Callahan, Michael R. McLaren